Nicolas Van de Velde

1.9k total citations
56 papers, 1.3k citations indexed

About

Nicolas Van de Velde is a scholar working on Infectious Diseases, Epidemiology and Health. According to data from OpenAlex, Nicolas Van de Velde has authored 56 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Infectious Diseases, 23 papers in Epidemiology and 17 papers in Health. Recurrent topics in Nicolas Van de Velde's work include SARS-CoV-2 and COVID-19 Research (20 papers), Vaccine Coverage and Hesitancy (17 papers) and HIV/AIDS Research and Interventions (16 papers). Nicolas Van de Velde is often cited by papers focused on SARS-CoV-2 and COVID-19 Research (20 papers), Vaccine Coverage and Hesitancy (17 papers) and HIV/AIDS Research and Interventions (16 papers). Nicolas Van de Velde collaborates with scholars based in United States, United Kingdom and Canada. Nicolas Van de Velde's co-authors include Marc Brisson, Marie‐Claude Boily, Mélanie Drolet, Philippe De Wals, Eduardo L. Franco, Giulio Maria Corbelli, Erika Castellanos, Benjamin Young, Brent Allan and Patricia Rios and has published in prestigious journals such as The Lancet, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Nicolas Van de Velde

54 papers receiving 1.2k citations

Peers

Countries citing papers authored by Nicolas Van de Velde

Since Specialization

Citations

This map shows the geographic impact of Nicolas Van de Velde's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Nicolas Van de Velde with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Nicolas Van de Velde more than expected).

Fields of papers citing papers by Nicolas Van de Velde

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Nicolas Van de Velde. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Nicolas Van de Velde. The network helps show where Nicolas Van de Velde may publish in the future.

Co-authorship network of co-authors of Nicolas Van de Velde

This figure shows the co-authorship network connecting the top 25 collaborators of Nicolas Van de Velde. A scholar is included among the top collaborators of Nicolas Van de Velde based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Nicolas Van de Velde. Nicolas Van de Velde is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical Impact and Cost-Effectiveness of Updated 2023/24 COVID-19 mRNA Vaccination in High-Risk Populations in the United States 2025 ·Infectious Diseases and Therapy ·Keya Joshi, (unknown), (unknown), Văn Hùng Nguyễn, (unknown), James A. Mansi, Nicolas Van de Velde, Ekkehard Beck	2
2	Vaccine preparation time, errors, satisfaction, and preference of prefilled syringes versus RSV vaccines requiring reconstitution: randomized, time and motion study 2024 ·Journal of Medical Economics ·(unknown), Samantha Kimball, (unknown), Serena Fossati, Matthias Hünger, (unknown), (unknown), (unknown), Nicolas Van de Velde	3
3	The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2024 vaccines in the United Kingdom 2024 ·Journal of Medical Economics ·Michele Kohli, Michael Maschio, (unknown), Keya Joshi, Stuart Carroll, Orsolya Balogh, Nicolas Van de Velde, Ekkehard Beck	2
4	Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged ≥ 65 years in the United States 2024 ·Vaccine ·(unknown), Christopher Bush, (unknown), Katherine E. Mues, Ekkehard Beck, Linwei Li, (unknown), (unknown), Morgan A. Marks, (unknown), Daina B. Esposito, David Martin, Nicolas Van de Velde	4
5	Immunogenicity of mRNA-1273 and BNT162b2 in Immunocompromised Patients: Systematic Review and Meta-analysis Using GRADE 2024 ·Infectious Diseases and Therapy ·(unknown), Katrin Haeussler, Xuan Wang, (unknown), Mary T. Bausch-Jurken, Pawana Sharma, Mohammadreza Amiri, (unknown), (unknown), (unknown), (unknown), Nicolas Van de Velde	4
6	Real-World Effectiveness of a Third Dose of mRNA-1273 Versus BNT162b2 on Inpatient and Medically Attended COVID-19 Among Immunocompromised US Adults 2024 ·Infectious Diseases and Therapy ·(unknown), Linwei Li, Katherine E. Mues, (unknown), (unknown), James A. Mansi, Nicolas Van de Velde, Ekkehard Beck	3
7	Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults 2023 ·Vaccines ·(unknown), Văn Hùng Nguyễn, Cathérine Boileau, Alina Bogdanov, (unknown), Thiérry Ducruet, Ni Zeng, (unknown), Daina B. Esposito, David Martin, Andrew Rosen, Nicolas Van de Velde, Sten H. Vermund, Stefan Gravenstein, James A. Mansi	17
8	Clinical impact and cost-effectiveness of the updated COVID-19 mRNA Autumn 2023 vaccines in Germany 2023 ·Journal of Medical Economics ·Keya Joshi, Stefan Scholz, Michael Maschio, Michele Kohli, Amy S. Lee, (unknown), B. Ultsch, Nicolas Van de Velde, Ekkehard Beck	9
9	The potential clinical impact and cost-effectiveness of the updated COVID-19 mRNA fall 2023 vaccines in the United States 2023 ·Journal of Medical Economics ·Michele Kohli, Michael Maschio, Keya Joshi, Amy S. Lee, (unknown), Ekkehard Beck, Nicolas Van de Velde, Milton C. Weinstein	16
10	Factors associated with receipt of mRNA-1273 vaccine at a United States national retail pharmacy during the COVID-19 pandemic 2023 ·Vaccine ·(unknown), Philip O. Buck, Renae L. Smith-Ray, Nicolas Van de Velde, Tanya Singh, James A. Mansi, (unknown), Michael Taitel	4
11	Patient preferences and health state utilities associated with the treatment process of antiretroviral therapy for people living with HIV 2022 ·Quality of Life Research ·Louis S. Matza, (unknown), Vasiliki Chounta, Nicolas Van de Velde	4
12	Correction to: Physical, Emotional, and Psychosocial Challenges Associated with Daily Dosing of HIV Medications and Their Impact on Indicators of Quality of Life: Findings from the Positive Perspectives Study 2021 ·AIDS and Behavior ·Patricia Rios, Chinyere Okoli, Erika Castellanos, Brent Allan, Benjamin Young, (unknown), Marvelous Muchenje, (unknown), Giulio Maria Corbelli, (unknown), William D. Hardy, Nicolas Van de Velde	2
13	Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four European countries 2021 ·Sexually Transmitted Infections ·Babatunde Akinwunmi, (unknown), (unknown), (unknown), Paolo Rizzini, Fabio Maria Vecchio, (unknown), Gaëlle Nachbaur, Laurent Finkielsztejn, Vasiliki Chounta, Nicolas Van de Velde	30
14	Shared Decision Making Between Patients and Healthcare Providers and its Association with Favorable Health Outcomes Among People Living with HIV 2020 ·AIDS and Behavior ·Chinyere Okoli, (unknown), Brent Allan, Erika Castellanos, Benjamin Young, (unknown), Giulio Maria Corbelli, (unknown), Marvelous Muchenje, Nicolas Van de Velde, Patricia Rios	32
15	Economic Impact of Introducing the RTS,S Malaria Vaccine: Cost-Effectiveness and Budget Impact Analysis in 41 Countries 2019 ·MDM Policy & Practice ·Christophe Sauboin, (unknown), Nicolas Van de Velde, Ilse Van Vlaenderen	12
16	Potential public health impact of RTS,S malaria candidate vaccine in sub-Saharan Africa: a modelling study 2015 ·Malaria Journal ·Christophe Sauboin, (unknown), Nicolas Van de Velde, Ilse Van Vlaenderen	8
17	Vaccinating Girls and Boys with Different Human Papillomavirus Vaccines: Can It Optimise Population-Level Effectiveness? 2013 ·PLoS ONE ·Mélanie Drolet, Marie‐Claude Boily, Nicolas Van de Velde, Eduardo L. Franco, Marc Brisson	7
18	The impact of differential uptake of HPV vaccine by sexual risks on health inequalities: A model-based analysis 2013 ·Vaccine ·Talía Malagón, (unknown), Marie‐Claude Boily, Nicolas Van de Velde, Mélanie Drolet, Marc Brisson	19
19	Population-Level Impact of the Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines: A Model–Based Analysis 2012 ·JNCI Journal of the National Cancer Institute ·Nicolas Van de Velde, Marie‐Claude Boily, Mélanie Drolet, Eduardo L. Franco, Marie‐Hélène Mayrand, Erich V. Kliewer, François Coutlée, Jean‐François Laprise, Talía Malagón, Marc Brisson	110
20	Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis 2010 ·Vaccine ·Nicolas Van de Velde, Marc Brisson, Marie‐Claude Boily	73

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact